SBF
ALNY icon

Sara-Bay Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sara-Bay Financial’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,750
Closed -$695K – 83
2025
Q4 		$695K Buy
1,750
+300
+21% +$133K 0.21% 36
2025
Q3 		$661K Hold
1,450
– – 0.18% 43
2025
Q2 		$473K Buy
1,450
+450
+45% +$125K 0.17% 49
2025
Q1 		$268K Buy
1,000
+15
+2% +$3.85K 0.12% 69
2024
Q4 		$232K Buy
985
+235
+31% +$61.8K 0.09% 82
2024
Q3 		$206K Buy
+750
New +$195K 0.07% 81

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sara-Bay Financial's ALNY Position: Q1 2026 in Review

Sara-Bay Financial sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,750 shares — an estimated $695K sold.

Sara-Bay Financial first reported a position in ALNY in Q3 2024 and held it in 6 quarters. The position peaked at $695K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Sara-Bay Financial reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Sara-Bay Financial sold 1,750 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $695K.
  • Sara-Bay Financial first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Sara-Bay Financial's Alnylam Pharmaceuticals position peaked at $695K in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Sara-Bay Financial's 13F filing for Q1 2026, filed 17 Apr 2026.